LENZ Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $147.0M
- Price
- $4.68
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.43%
- Volume
- 475.3K
About
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Quick stats
Shares outstanding31.4M
Computed float14.1M
Float / shares44.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001815776
Websitehttps://www.lenz-tx.com
AI Summary
AI-generated1/18
majorbullishearnings
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, comprised of $1.7 million in VIZZ product sales—a 9% sequential increase—and $3.8 million in license revenue. The company ended the quarter with a strong cash position of $220.0 million to support its commercial launch activities.
Commercial traction appears robust, with over 60% of ePharmacy patients purchasing multiple monthly packs and refill cohorts tracking to an average of five packs annually. The company expanded patient access in July by launching a telehealth prescribing channel and a national TV campaign featuring brand spokesperson Sarah Jessica Parker.
Internationally, LENZ advanced its strategy by submitting regulatory filings in the UK, Canada, and Saudi Arabia, and securing partnerships in Australia/New Zealand with Arrotex and Greater China via Everest Medicines. These agreements carry potential total milestone payments of up to $65 million and $85 million, respectively.
Red flags
- Net loss widened to $31.9 million from $14.9 million in the prior year period due to increased SG&A expenses associated with the commercial launch